glycine has been researched along with Shock, Septic in 18 studies
Shock, Septic: Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Our previous studies showed that 20-HETE mimetic, N -(20-hydroxyeicosa-5[Z],14[Z]-dienoyl)glycine (5,14-HEDGE), protects against vascular hyporeactivity, hypotension, tachycardia, and arterial inflammation induced by lipopolysaccharide (LPS) in rats." | 4.12 | Activation of GPR75 Signaling Pathway Contributes to the Effect of a 20-HETE Mimetic, 5,14-HEDGE, to Prevent Hypotensive and Tachycardic Responses to Lipopolysaccharide in a Rat Model of Septic Shock. ( Anugu, RR; Bahceli, O; Falck, JR; Guden, DS; Horat, MF; Malik, KU; Sahan-Firat, S; Sari, AN; Senol, SP; Temiz-Resitoglu, M; Tunctan, B; Yilmaz, DE, 2022) |
| " LPS-induced pulmonary vascular injury was significantly attenuated in rats with methotrexate-induced leukocytopenia or treated with ONO-5046, a potent granulocyte elastase inhibitor, although ONO-5046 did not inhibit the LPS-induced increase in serum FDP (E)." | 3.69 | Endotoxin-induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats. ( Murakami, K; Okabe, H; Okajima, K; Takatsuki, K; Uchiba, M, 1995) |
| " The association of hypoglycemia and increased arterial alanine and glycine with elevated plasma glucagon implied impaired gluconeogenesis." | 3.66 | Amino acid metabolism in dogs with E. coli bacteremic shock. ( Duff, JH; Groves, AC; Woolf, LI, 1979) |
| "Human Gram-negative septic shock, frequently seen in intensive care units, is a condition with high mortality." | 2.41 | Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock. ( Basu, S; Eriksson, M; Eriksson, O; Kiiski, R; Larsson, A; Mattsson, C; Nordgren, A, 2000) |
| "Glycine has been well characterized in spinal cord as an inhibitory neurotransmitter which activates a glycine-gated chloride channel (GlyR) expressed in postsynaptic membranes." | 2.40 | Glycine: a new anti-inflammatory immunonutrient. ( Bradford, B; Enomoto, N; Ikejema, K; Rose, ML; Rusyn, I; Schemmer, P; Seabra, V; Stacklewitz, RF; Thurman, RG; Wheeler, MD; Yin, M; Zhong, Z, 1999) |
| "Endotoxic shock is a systemic inflammatory response that is associated with an increase in nitric oxide production and a decrease in the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), which may contribute to the fall in blood pressure and vascular reactivity." | 1.35 | A 20-hydroxyeicosatetraenoic acid agonist, N-[20-hydroxyeicosa-5(Z),14(Z)-dienoyl]glycine, opposes the fall in blood pressure and vascular reactivity in endotoxin-treated rats. ( Anjaiah, S; Buharalioglu, CK; Falck, J; Firat, SS; Korkmaz, B; Malik, KU; Roman, RJ; Tunctan, B, 2008) |
| "[15N]glycine (100mg) was given orally to children (mean age 5." | 1.32 | Assessment of whole body protein metabolism in critically ill children: can we use the [15N]glycine single oral dose method? ( Deutz, NE; Forget, PP; Hoos, MB; Jansen, NJ; van Kreel, BK; van Waardenburg, DA; Vos, GD; Wagenmakers, AJ, 2004) |
| "Mortality associated with endotoxin shock is likely mediated by Kupffer cells, alveolar macrophages, and circulating neutrophils." | 1.31 | Dietary glycine blunts lung inflammatory cell influx following acute endotoxin. ( Enomoto, N; Madren, J; Rose, ML; Seabra, V; Thurman, RG; Wheeler, MD; Yamashima, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (16.67) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Tunctan, B | 2 |
| Senol, SP | 1 |
| Temiz-Resitoglu, M | 1 |
| Yilmaz, DE | 1 |
| Guden, DS | 1 |
| Bahceli, O | 1 |
| Horat, MF | 1 |
| Sahan-Firat, S | 1 |
| Sari, AN | 1 |
| Falck, JR | 1 |
| Anugu, RR | 1 |
| Malik, KU | 2 |
| Hagiwara, S | 1 |
| Iwasaka, H | 1 |
| Togo, K | 1 |
| Noguchi, T | 1 |
| Yende, S | 1 |
| van Waardenburg, DA | 1 |
| Deutz, NE | 1 |
| Hoos, MB | 1 |
| Jansen, NJ | 1 |
| van Kreel, BK | 1 |
| Vos, GD | 1 |
| Wagenmakers, AJ | 1 |
| Forget, PP | 1 |
| Li, L | 1 |
| Bhatia, M | 1 |
| Zhu, YZ | 1 |
| Zhu, YC | 1 |
| Ramnath, RD | 1 |
| Wang, ZJ | 1 |
| Anuar, FB | 1 |
| Whiteman, M | 1 |
| Salto-Tellez, M | 1 |
| Moore, PK | 1 |
| Korkmaz, B | 1 |
| Buharalioglu, CK | 1 |
| Firat, SS | 1 |
| Anjaiah, S | 1 |
| Falck, J | 1 |
| Roman, RJ | 1 |
| Uchiba, M | 1 |
| Okajima, K | 1 |
| Murakami, K | 1 |
| Okabe, H | 1 |
| Takatsuki, K | 1 |
| Ikejima, K | 1 |
| Iimuro, Y | 1 |
| Forman, DT | 1 |
| Thurman, RG | 3 |
| Hattori, K | 1 |
| Hirano, T | 1 |
| Ushiyama, C | 1 |
| Miyajima, H | 1 |
| Yamakawa, N | 1 |
| Ebata, T | 1 |
| Wada, Y | 1 |
| Ikeda, S | 1 |
| Yoshino, K | 2 |
| Tateno, M | 1 |
| Oshimi, K | 1 |
| Kayagaki, N | 1 |
| Yagita, H | 2 |
| Okumura, K | 1 |
| Eriksson, M | 2 |
| Larsson, A | 2 |
| Saldeen, T | 1 |
| Mattsson, C | 2 |
| Wheeler, MD | 2 |
| Rose, ML | 2 |
| Yamashima, S | 1 |
| Enomoto, N | 2 |
| Seabra, V | 2 |
| Madren, J | 1 |
| Basu, S | 1 |
| Eriksson, O | 1 |
| Kiiski, R | 1 |
| Nordgren, A | 1 |
| Yamada, K | 1 |
| Sekikawa, K | 1 |
| Madarame, H | 1 |
| Nakane, A | 1 |
| Ikejema, K | 1 |
| Stacklewitz, RF | 1 |
| Zhong, Z | 1 |
| Yin, M | 1 |
| Schemmer, P | 1 |
| Rusyn, I | 1 |
| Bradford, B | 1 |
| Quasney, MW | 1 |
| Waterer, GW | 1 |
| Dahmer, MK | 1 |
| Turner, D | 1 |
| Zhang, Q | 1 |
| Cantor, RM | 1 |
| Wunderink, RG | 1 |
| Woolf, LI | 1 |
| Groves, AC | 1 |
| Duff, JH | 1 |
| Ishida, K | 1 |
| Totsuka, M | 1 |
| Hayasaka, H | 1 |
| Agarwal, MK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Double Blind Randomized Controlled Trial of High Dose Vitamin B12 in Septic Shock[NCT03783091] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-08-05 | Recruiting | ||
| Hydrogen Sulfide as Prognostic Factor[NCT01088490] | 50 participants (Actual) | Observational | 2010-01-31 | Completed | |||
| Controlled and Randomized Clinical Trial for Evaluating the Effect of a Supplement of Glycine as Adjuvant in the Treatment of COVID-19 Pneumonia in Patients Initiating Mechanical Ventilation[NCT04443673] | 59 participants (Actual) | Interventional | 2020-06-15 | Terminated (stopped due to An interim analysis showed no difference in major outcomes (n=35 glycine and n=24 control participants)) | |||
| Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis[NCT01417481] | Phase 2 | 13 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to Some of the researchers finished their participation in the study.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.3908 |
| Placebo | 0.2035 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.0819 |
| Placebo | 0.1668 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|---|
| Glycine | -0.00007 |
| Placebo | 0.1739 |
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~Each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Cough questionnaire score | Appetite questionnaire score | Energy questionnaire score | Body weight | Height | Heart rate | Respiratory rate | Temperature | |
| Glycine | 81.1 | 89.1 | 84.6 | 101.6 | 100.5 | 103.5 | 94.8 | 100.0 |
| Placebo | 89.1 | 132.1 | 111.5 | 103.6 | 100.5 | 98.1 | 109.0 | 100.1 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Forced expiratory volume at first second (FEV1) | Forced expiratory flow at 25%FVC (FEF25) | Maximal forced expiratory flow (FEFmax, PEFR) | |
| Glycine | 109.7 | 133.9 | 115.3 |
| Placebo | 91.4 | 83.3 | 91.2 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | |
|---|---|---|
| Forced vital capacity (FVC) | Forced expiratory flow at 75%FVC (FEF75) | |
| Glycine | 104.1 | 111.8 |
| Placebo | 100.6 | 108.9 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Peripheral oxygen saturation (SpO2) | FEV1/FVC | Forced expiratory flow at 50%FVC (FEF50) | |
| Glycine | 105.2 | 105.2 | 115.5 |
| Placebo | 98.9 | 94.9 | 93.1 |
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~In the symptoms questionnaire, each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) | ||
|---|---|---|---|
| Sputum questionnaire score | Dyspnea questionnaire score | Total questionnaire score | |
| Glycine | 82.0 | 75.6 | 77.7 |
| Placebo | 102.6 | 103.8 | 98.7 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myeloperoxidase | IL-1 | IL-4 | IL-6 | IL-7 | IL-8 | IL-12 | IL-13 | G-CSF | IFN-gamma | MCP-1 | MIP-1beta | |
| Glycine | -0.4361 | -0.1635 | 0.2964 | 0.0085 | 0.0356 | -0.1466 | 0.3203 | -0.0561 | -0.0776 | 0.3272 | -0.0836 | 0.0330 |
| Placebo | -0.2906 | -0.0352 | 0.1470 | 0.2255 | 0.0819 | -0.2364 | 0.2603 | 0.1953 | 0.2272 | 0.3639 | 0.0472 | -0.0608 |
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myeloperoxidase | IL-1 | IL-2 | IL-4 | IL-5 | IL-7 | IL-8 | IL-10 | IL-12 | IL-13 | IL-17 | IFN-gamma | MCP-1 | MIP-1beta | TNF-alpha | GM-CSF | |
| Glycine | 0.1294 | -0.0918 | 0.0233 | -0.0161 | 0.2498 | 0.0611 | -0.0824 | 0.0549 | 0.1675 | 0.1630 | 0.0680 | 0.0248 | 0.0042 | -0.0303 | 0.0412 | -0.0538 |
| Placebo | 0.0669 | -0.0102 | -0.0274 | 0.0522 | 0.1304 | 0.1387 | 0.0542 | 0.0074 | 0.0677 | 0.0953 | 0.1140 | 0.0649 | 0.2608 | 0.0977 | 0.1568 | -0.0822 |
2 reviews available for glycine and Shock, Septic
| Article | Year |
|---|---|
Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock.
Topics: Animals; Azetidines; Benzylamines; Glycine; Humans; Shock, Septic; Thrombin | 2000 |
Glycine: a new anti-inflammatory immunonutrient.
Topics: Alcohols; Animals; Anti-Inflammatory Agents; Calcium Channels, L-Type; Chloride Channels; Cyclospori | 1999 |
16 other studies available for glycine and Shock, Septic
| Article | Year |
|---|---|
Activation of GPR75 Signaling Pathway Contributes to the Effect of a 20-HETE Mimetic, 5,14-HEDGE, to Prevent Hypotensive and Tachycardic Responses to Lipopolysaccharide in a Rat Model of Septic Shock.
Topics: Animals; Arteritis; Cell Cycle Proteins; ErbB Receptors; Glycine; Hydroxyeicosatetraenoic Acids; Hyp | 2022 |
A neutrophil elastase inhibitor, sivelestat, reduces lung injury following endotoxin-induced shock in rats by inhibiting HMGB1.
Topics: Animals; Glycine; HMGB1 Protein; Interleukin-6; Leukocyte Elastase; Lipopolysaccharides; Lung; Lung | 2008 |
Role of toll-like receptor 4 mutations in gram-negative septic shock.
Topics: Aspartic Acid; Confounding Factors, Epidemiologic; Drosophila Proteins; Genetic Predisposition to Di | 2002 |
Assessment of whole body protein metabolism in critically ill children: can we use the [15N]glycine single oral dose method?
Topics: Child; Child, Preschool; Critical Illness; Female; Glycine; Humans; Infant; Male; Meningococcal Infe | 2004 |
Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse.
Topics: Alkynes; Animals; Extracellular Signal-Regulated MAP Kinases; Glycine; Hydrogen Sulfide; Inflammatio | 2005 |
Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse.
Topics: Alkynes; Animals; Extracellular Signal-Regulated MAP Kinases; Glycine; Hydrogen Sulfide; Inflammatio | 2005 |
Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse.
Topics: Alkynes; Animals; Extracellular Signal-Regulated MAP Kinases; Glycine; Hydrogen Sulfide; Inflammatio | 2005 |
Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse.
Topics: Alkynes; Animals; Extracellular Signal-Regulated MAP Kinases; Glycine; Hydrogen Sulfide; Inflammatio | 2005 |
A 20-hydroxyeicosatetraenoic acid agonist, N-[20-hydroxyeicosa-5(Z),14(Z)-dienoyl]glycine, opposes the fall in blood pressure and vascular reactivity in endotoxin-treated rats.
Topics: Animals; Blood Pressure; Endotoxins; Glycine; Heart Rate; Hydroxyeicosatetraenoic Acids; Inflammatio | 2008 |
Endotoxin-induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats.
Topics: Amino Acid Chloromethyl Ketones; Amino Acid Sequence; Animals; Anticoagulants; Antithrombin III; Cap | 1995 |
A diet containing glycine improves survival in endotoxin shock in the rat.
Topics: Animal Feed; Animals; Calcium; Cells, Cultured; Disease Models, Animal; Glycine; Ischemia; Kupffer C | 1996 |
A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice.
Topics: Animals; Crosses, Genetic; Fas Ligand Protein; Female; Glycine; Graft vs Host Disease; Humans; Hydro | 1997 |
Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig.
Topics: Animals; Azetidines; Benzylamines; Blood Coagulation; Creatinine; Diuresis; Drug Evaluation, Preclin | 1998 |
Dietary glycine blunts lung inflammatory cell influx following acute endotoxin.
Topics: Acute Disease; Animals; Calcium; Cells, Cultured; Dietary Supplements; Drug Administration Schedule; | 2000 |
Dietary glycine blunts lung inflammatory cell influx following acute endotoxin.
Topics: Acute Disease; Animals; Calcium; Cells, Cultured; Dietary Supplements; Drug Administration Schedule; | 2000 |
Dietary glycine blunts lung inflammatory cell influx following acute endotoxin.
Topics: Acute Disease; Animals; Calcium; Cells, Cultured; Dietary Supplements; Drug Administration Schedule; | 2000 |
Dietary glycine blunts lung inflammatory cell influx following acute endotoxin.
Topics: Acute Disease; Animals; Calcium; Cells, Cultured; Dietary Supplements; Drug Administration Schedule; | 2000 |
Effect of a matrix metalloproteinase inhibitor on host resistance against Listeria monocytogenes infection.
Topics: Animals; Antibodies, Monoclonal; Colony Count, Microbial; Fas Ligand Protein; Female; Glycine; Hydro | 2000 |
Intracellular adhesion molecule Gly241Arg polymorphism has no impact on ARDS or septic shock in community-acquired pneumonia.
Topics: Arginine; Community-Acquired Infections; Genetic Predisposition to Disease; Glycine; Humans; Interce | 2002 |
Amino acid metabolism in dogs with E. coli bacteremic shock.
Topics: Alanine; Amino Acids; Animals; Blood Gas Analysis; Blood Pressure; Blood Urea Nitrogen; Dogs; Escher | 1979 |
[Alanine metabolism in the skeletal muscle and plasma in endotoxemia].
Topics: Alanine; Animals; Glycine; Muscles; Proline; Rabbits; Sepsis; Shock, Septic | 1985 |
Neurotransmitting substances and endotoxin respone in relation to hepatic enzyme induction.
Topics: Aminobutyrates; Animals; Chloromercuribenzoates; Cortisone; Cyproheptadine; Dihydroxyphenylalanine; | 1974 |